Registered title, quoted from ClinicalTrials.gov
Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma
An open trial on osteosarcoma, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07648069, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to 70 years; sex: all
Registered eligibility fields
Pathologically diagnosed as solid tumors, including bone or soft tissue sarcoma, and staging for advanced or unresectable patients ;
Inclusion criterion 3
1. Before any procedures related to the research program, including screening and evaluation stage, signed informed consent.
Exclusion criterion 1
Age≥18 years old, and≤70 years old ; 3. Pathologically diagnosed as solid tumors, including bone or soft tissue sarcoma, and staging for advanced or unresectable patients ; 4. Patients with first-line treatment failure ; 5. No previous tumor vaccine treatment ; no previous treatment with PD-1 antibody ; 6. According to the RECIST1.1 standard, there are measurable lesions and superficial lesions ; 7. The following three screening indicators should be met in the test screening period:
Exclusion criterion 2
absolute neutrophil count ( ANC ) ≥ 1.5 × 109 / L ( without GCSF support ) ;
Inclusion criterion 9
platelet ( PLT ) ≥ 75 × 109 / L;
Inclusion criterion 11
hemoglobin ≥ 90g / dL ( no blood transfusion in the past 7 days ) ;
Inclusion criterion 12
serum creatinine ≤ 1.5 × ULN ( upper limit of normal ) ; 24-hour creatinine clearance rate ≥ 60 mL / min;
Inclusion criterion 15
Aspartate Aminotransferase (AST/SGOT) ≤ 2 × ULN;
Inclusion criterion 16
Alanine Aminotransferase (ALT/SGPT) ≤ 2 × ULN;
Inclusion criterion 17
total bilirubin ( TBIL ) ≤ 1 × ULN 13. Females with fertility were negative in pregnancy test before treatment ; consent must be given to the use of contraception or the prohibition of same-sex or opposite-sex sexual activity during treatment; 14. During the whole experiment, we can regularly go to the research institutions to carry out relevant testing, evaluation and management.
Inclusion criterion 18
absolute neutrophil count ( ANC ) ≥ 1.5 × 109 / L ( without GCSF support ) ;
Exclusion criterion 4
platelet ( PLT ) ≥ 75 × 109 / L;
Exclusion criterion 6
hemoglobin ≥ 90g / dL ( no blood transfusion in the past 7 days ) ;
Exclusion criterion 7
serum creatinine ≤ 1.5 × ULN ( upper limit of normal ) ; 24-hour creatinine clearance rate ≥ 60 mL / min;
Exclusion criterion 10
Aspartate Aminotransferase (AST/SGOT) ≤ 2 × ULN;
Exclusion criterion 11
Alanine Aminotransferase (ALT/SGPT) ≤ 2 × ULN;
Exclusion criterion 12
total bilirubin ( TBIL ) ≤ 1 × ULN 13. Females with fertility were negative in pregnancy test before treatment ; consent must be given to the use of contraception or the prohibition of same-sex or opposite-sex sexual activity during treatment; 14. During the whole experiment, we can regularly go to the research institutions to carry out relevant testing, evaluation and management.
Exclusion criterion 13
According to the RECIST1.1 standard, there are measurable lesions and superficial lesions ;
Inclusion criterion 6
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; day-to-day activity level; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07648069, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Before any procedures related to the research program, including screening and evaluation stage, signed informed consent.
- Age≥18 years old, and≤70 years old ;
- Pathologically diagnosed as solid tumors, including bone or soft tissue sarcoma, and staging for advanced or unresectable patients ;
- Patients with first-line treatment failure ;
- No previous tumor vaccine treatment ; no previous treatment with PD-1 antibody ;
- According to the RECIST1.1 standard, there are measurable lesions and superficial lesions ;
- The following three screening indicators should be met in the test screening period:
(1)The available tumor tissue samples ( paraffin sections and fresh surgical specimens ) were used for subsequent whole exome and transcriptome sequencing analysis and primary cell culture to obtain tumor neoantigen-related mutation sequence information and gene expression.
( 2 ) Available peripheral blood samples; ( 3 ) Tumor new antigen prediction analysis and in vitro laboratory testing; 8. ECOG score 0-1 ( see Appendix ) and expected survival time greater than 6 months ; 9. Patients were not allowed to use anti-tumor drugs and radiotherapy within 4 weeks before vaccination; 10. Patients with brain metastasis who were stable for at least one month after treatment can be included; 11. echocardiography showed left ventricular ejection fraction ≥ 50 %; 12. The results of laboratory tests should meet at least the following indicators :
- White blood cell count ≥ 3.0 × 109 / L;
- absolute neutrophil count ( ANC ) ≥ 1.5 × 109 / L ( without GCSF support ) ;
- absolute lymphocyte count ( ALC ) ≥ 1.0 × 109 / L;
- platelet ( PLT ) ≥ 75 × 109 / L;
- hemoglobin ≥ 90g / dL ( no blood transfusion in the past 7 days ) ;
- Prothrombin time or INR ≤ 1.5x normal upper limit time, unless receiving anticoagulant therapy;
- partial thromboplastin time ( APTT ) ≤ 1.5x normal upper limit time, unless receiving anticoagulant therapy;
- serum creatinine ≤ 1.5 × ULN ( upper limit of normal ) ; 24-hour creatinine clearance rate ≥ 60 mL / min;
- Aspartate Aminotransferase (AST/SGOT) ≤ 2 × ULN;
- Alanine Aminotransferase (ALT/SGPT) ≤ 2 × ULN;
- total bilirubin ( TBIL ) ≤ 1 × ULN 13. Females with fertility were negative in pregnancy test before treatment ; consent must be given to the use of contraception or the prohibition of same-sex or opposite-sex sexual activity during treatment; 14. During the whole experiment, we can regularly go to the research institutions to carry out relevant testing, evaluation and management.
Exclusion Criteria:
- 1. Before any procedures related to the research program, including screening and evaluation stage, signed informed consent.
- Age≥18 years old, and≤70 years old ; 3. Pathologically diagnosed as solid tumors, including bone or soft tissue sarcoma, and staging for advanced or unresectable patients ; 4. Patients with first-line treatment failure ; 5. No previous tumor vaccine treatment ; no previous treatment with PD-1 antibody ; 6. According to the RECIST1.1 standard, there are measurable lesions and superficial lesions ; 7. The following three screening indicators should be met in the test screening period:
(1)The available tumor tissue samples ( paraffin sections and fresh surgical specimens ) were used for subsequent whole exome and transcriptome sequencing analysis and primary cell culture to obtain tumor neoantigen-related mutation sequence information and gene expression.
( 2 ) Available peripheral blood samples; ( 3 ) Tumor new antigen prediction analysis and in vitro laboratory testing; 8. ECOG score 0-1 ( see Appendix ) and expected survival time greater than 6 months ; 9. Patients were not allowed to use anti-tumor drugs and radiotherapy within 4 weeks before vaccination; 10. Patients with brain metastasis who were stable for at least one month after treatment can be included; 11. echocardiography showed left ventricular ejection fraction ≥ 50 %; 12. The results of laboratory tests should meet at least the following indicators :
- White blood cell count ≥ 3.0 × 109 / L;
- absolute neutrophil count ( ANC ) ≥ 1.5 × 109 / L ( without GCSF support ) ;
- absolute lymphocyte count ( ALC ) ≥ 1.0 × 109 / L;
- platelet ( PLT ) ≥ 75 × 109 / L;
- hemoglobin ≥ 90g / dL ( no blood transfusion in the past 7 days ) ;
- Prothrombin time or INR ≤ 1.5x normal upper limit time, unless receiving anticoagulant therapy;
- partial thromboplastin time ( APTT ) ≤ 1.5x normal upper limit time, unless receiving anticoagulant therapy;
- serum creatinine ≤ 1.5 × ULN ( upper limit of normal ) ; 24-hour creatinine clearance rate ≥ 60 mL / min;
- Aspartate Aminotransferase (AST/SGOT) ≤ 2 × ULN;
- Alanine Aminotransferase (ALT/SGPT) ≤ 2 × ULN;
- total bilirubin ( TBIL ) ≤ 1 × ULN 13. Females with fertility were negative in pregnancy test before treatment ; consent must be given to the use of contraception or the prohibition of same-sex or opposite-sex sexual activity during treatment; 14. During the whole experiment, we can regularly go to the research institutions to carry out relevant testing, evaluation and management.
Quoted from ClinicalTrials.gov, NCT07648069, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07648069, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.